中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFR(del19/T790M/C797S) and EGFR(L858R/T790M/C797S))

文献类型：期刊论文

作者Fang, Haotian3,4; Wu, Yingming2; Xiao, Qitao1,2; He, Dongbo2; Zhou, Tongrui2; Liu, Wenzhong2; Yang, Chun-Hao3,4; Xie, Yuli2
刊名BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
出版日期2022-09-15
卷号72页码:11
ISSN号0960-894X
关键词Non-small cell lung cancer EGFR Triple mutations C797S EGFR-TKIs
DOI10.1016/j.bmcl.2022.128729
通讯作者Xie, Yuli(ylxie@wigenbio.com)
英文摘要Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have demonstrated encouraging clinical outcomes for patients with EGFR-mutated non-small cell lung cancer, a considerable number of patients will develop drug resistance and eventually undergo disease progression after taking EGFR-TKIs for a period of time. EGFR(del19/T790M/C797S) and EGFR(L858R/T790M/C797S) are two most prevalent tertiary EGFR mutants identified in Osimertinib-resistant tumors and currently there is no therapy approved clinically targeting these mutants. In this study, we designed and synthesized a series of novel 4th generation EGFR inhibitors based on scaffold of Brigatinib. After extensive SAR studies, compound 23, the most promising candidate, exhibited strong biochemical potencies against EGFR(del19/T790M/C797S), EGF(L858R/T790M/C797S) and other clinically relevant EGFR mutants while sparing wild type EGFR. In cellular assays, compound 23 potently inhibited proliferation of BaF3EGFR (el19/T790M/C797S) and PC-9EGFR (del19/T790M/C797S). Moreover, compound 23 demonstrated good DMPK profile in mouse PK study.
WOS关键词OSIMERTINIB ; RESISTANCE ; MECHANISMS ; THERAPY
WOS研究方向Pharmacology & Pharmacy ; Chemistry
语种英语
出版者PERGAMON-ELSEVIER SCIENCE LTD
WOS记录号WOS:000814727000003
源URL[http://119.78.100.183/handle/2S10ELR8/301812]  
专题中国科学院上海药物研究所
通讯作者Xie, Yuli
作者单位1.Shanghai Blueray Biopharm Co Ltd, Bldg 3,576,Libing Rd, Shanghai 201210, Peoples R China
2.Wigen Biomed Technol Shanghai Co Ltd, 11Lane 67,Libing Rd, Shanghai 201210, Peoples R China
3.Univ Chinese Acad Sci, 19(A) Yuquan Rd,Shijingshan Dist, Beijing 100049, Peoples R China
4.Chinese Acad Sci, Shanghai Inst Mat Med, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China
推荐引用方式
GB/T 7714		 Fang, Haotian,Wu, Yingming,Xiao, Qitao,et al. Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFR(del19/T790M/C797S) and EGFR(L858R/T790M/C797S))[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,2022,72:11.
APA Fang, Haotian.,Wu, Yingming.,Xiao, Qitao.,He, Dongbo.,Zhou, Tongrui.,...&Xie, Yuli.(2022).Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFR(del19/T790M/C797S) and EGFR(L858R/T790M/C797S)).BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,72,11.
MLA Fang, Haotian,et al."Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFR(del19/T790M/C797S) and EGFR(L858R/T790M/C797S))".BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 72(2022):11.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。